The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer
Status:
Recruiting
Trial end date:
2022-11-17
Target enrollment:
Participant gender:
Summary
Gastric cancer is one of the most common malignant tumors of the digestive tract. Gastric
cancer patients diagnosed for the first time in China have a higher proportion of advanced
stages and a higher postoperative metastasis rate.Studies have shown that patients with good
pathological response after preoperative neoadjuvant therapy (such as tumor regression grade,
TRG0 or 1) have a better prognosis.The purpose of this study is to treat patients with
advanced gastric cancer who are difficult to perform R0 surgery with chemotherapy combined
with immunotherapy. At the same time as the primary cancerous lesions are reduced, the
distant metastatic lesions are effectively controlled in order to perform R0 surgery and to
improve the survival rate of patients with advanced gastric cancer.